Clinical Trial

Impact of Local Lidocaine Paravertebral Cervical Injection on Cervicogenic Dizziness Symptoms

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2025 (before its estimated September 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
at least 42 patients affected by cervicogenic dizziness will be allocated to the experimental group or in the placebo group. in the first group patients will received 2 paravertebral intramuscular injection of lidocaine 0.5% while in the placebo group they will received saline solution with the same injection technique. patients will be evaluated by subjective and objective testing before the treatment, immediatly and 3 months after the treatment.
Trial Details
NCT Number NCT07053176
Lead Sponsor Uniter Onlus
Conditions Cervicogenic Dizziness
Enrollment 42 participants
Start Date 2025-08-01
Primary Completion 2025-09-15 (estimated)
Study Completion 2025-09-15 (estimated)
Updated on ClinicalTrials.gov 2025-07-08